Egetis Therapeutics Gestione

Gestione criteri di controllo 2/4

Egetis Therapeutics Il CEO è Nicklas Westerholm, nominato in Jun2017, ha un mandato di 7.42 anni. possiede direttamente 0.068% delle azioni della società, per un valore di SEK 1.30M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.4 anni e 6.4 anni.

Informazioni chiave

Nicklas Westerholm

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.4yrs
Proprietà del CEO	0.07%
Durata media del management	7.4yrs
Durata media del Consiglio di amministrazione	6.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Nicklas Westerholm rispetto agli utili di Egetis Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-SEK 319m
Jun 30 2024	n/a	n/a	-SEK 319m
Mar 31 2024	n/a	n/a	-SEK 327m
Dec 31 2023	n/a	n/a	-SEK 327m
Sep 30 2023	n/a	n/a	-SEK 319m
Jun 30 2023	n/a	n/a	-SEK 286m
Mar 31 2023	n/a	n/a	-SEK 240m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 194m
Sep 30 2022	n/a	n/a	-SEK 148m
Jun 30 2022	n/a	n/a	-SEK 113m
Mar 31 2022	n/a	n/a	-SEK 114m
Dec 31 2021	SEK 5m	SEK 3m	-SEK 104m
Sep 30 2021	n/a	n/a	-SEK 147m
Jun 30 2021	n/a	n/a	-SEK 153m
Mar 31 2021	n/a	n/a	-SEK 155m
Dec 31 2020	SEK 4m	SEK 2m	-SEK 178m
Sep 30 2020	n/a	n/a	-SEK 127m
Jun 30 2020	n/a	n/a	-SEK 134m
Mar 31 2020	n/a	n/a	-SEK 127m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 61m
Sep 30 2019	n/a	n/a	-SEK 61m
Jun 30 2019	n/a	n/a	-SEK 48m
Mar 31 2019	n/a	n/a	-SEK 46m
Dec 31 2018	SEK 3m	SEK 2m	-SEK 85m
Sep 30 2018	n/a	n/a	-SEK 95m
Jun 30 2018	n/a	n/a	-SEK 103m
Mar 31 2018	n/a	n/a	-SEK 91m
Dec 31 2017	SEK 1m	SEK 1m	-SEK 88m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Nicklas sia ragionevole rispetto ad aziende di dimensioni simili nel mercato UK.

Compensazione vs guadagni: La retribuzione di Nicklas è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Nicklas Westerholm (48 yo)

7.4yrs

Mandato

SEK 5,900,000

Compensazione

Mr. Nicklas Westerholm has been the Chief Executive Officer of Egetis Therapeutics AB (publ) (formerly known as PledPharma AB (publ)) since June 16, 2017. Mr. Westerholm has been working in the AstraZeneca...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Nicklas Westerholm	Chief Executive Officer	7.4yrs	SEK 5.90m	0.068% SEK 1.3m
Torsten Almén	Founder	18.8yrs	Nessun dato	Nessun dato
Ingemar Lundström	Founder	18.8yrs	Nessun dato	Nessun dato
Louis Ignarro	Founder	18.8yrs	Nessun dato	Nessun dato
Heidi Brurok	Founder	18.8yrs	Nessun dato	Nessun dato
Rob Towart	Founder	18.8yrs	Nessun dato	Nessun dato
Yilmaz Mahshid	Chief Financial Officer	3.4yrs	Nessun dato	0.087% SEK 1.7m
Katayoun Welin-Berger	Vice President of Operations	1.7yrs	Nessun dato	Nessun dato
Jacques Näsström	Chief Scientific Officer	no data	SEK 655.00k	Nessun dato
Karl Hard	VP and Head of Investor Relations & Communication	2.8yrs	Nessun dato	Nessun dato
Laetitia Szaller	General Counsel & Head of Compliance	less than a year	Nessun dato	Nessun dato
Peter Verwaijen	Global Head of Marketing & Brand Strategy	2.5yrs	Nessun dato	Nessun dato

7.4yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di 0ABW è esperto e expertise (durata media dell'incarico 7.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Dart	Member of Scientific Advisory Board	6.4yrs	Nessun dato	Nessun dato
Mats Blom	Chairman of the Board	3.6yrs	SEK 300.00k	0.87% SEK 16.7m
Behshad Sheldon	Independent Director	1.8yrs	Nessun dato	Nessun dato
Thomas Lonngren	Director	3.6yrs	SEK 600.00k	0.079% SEK 1.5m
Gunilla Osswald	Independent Director	7.8yrs	SEK 200.00k	0.011% SEK 213.5k
Elisabeth Svanberg	Independent Director	7.8yrs	SEK 200.00k	0.010% SEK 201.2k
Laura James	Member of Scientific Advisory Board	6.4yrs	Nessun dato	Nessun dato
James Dear	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

6.4yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0ABW sono considerati esperti (durata media dell'incarico 6.4 anni).

Egetis Therapeutics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2025

Egetis Therapeutics AB (Publ) Announces Resignation of Peder Walberg from the Board of Directors

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Insider recently bought kr134k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Recent updates

Forecast breakeven date moved forward to 2025

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.34 loss in 3Q 2023)

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2025

New minor risk - Shareholder dilution

Egetis Therapeutics AB (Publ) Announces Resignation of Peder Walberg from the Board of Directors

Egetis Submits A Patent Application to the United States Patent and Trademark Office for Processes of Preparation of Tiratricol

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings released: kr0.25 loss per share (vs kr0.32 loss in 2Q 2023)

Egetis Therapeutics AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

Egetis Therapeutics AB (publ) Announces Topline Results of the Phase 2 Triac Trial II with Emcitate (Tiratricol) for MCT8 Deficiency

First quarter 2024 earnings released: kr0.26 loss per share (vs kr0.31 loss in 1Q 2023)

Full year 2023 earnings released: kr1.27 loss per share (vs kr1.00 loss in FY 2022)

Egetis Therapeutics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA

Third quarter 2023 earnings released: kr0.34 loss per share (vs kr0.25 loss in 3Q 2022)

Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency

Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency

Second quarter 2023 earnings released: kr0.32 loss per share (vs kr0.17 loss in 2Q 2022)

Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024

Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial

Insider recently bought kr134k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Forecast breakeven date pushed back to 2025

Independent Director recently bought kr206k worth of stock

Director recently bought kr992k worth of stock

Egetis Terminates Discussions Regarding Potential Acquisition

Less than half of directors are independent

First quarter 2023 earnings released: kr0.31 loss per share (vs kr0.17 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021)

Less than half of directors are independent

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media